Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSJ148 for HCMV Prevention in Stem Cell Transplant
NCT02268526Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2015
- Primary completion
- Dec 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of CSJ148 in cytomegalovirus infection (CMV), sponsored by Novartis. Started Jun 2015; status: completed.
02
Drugs
CSJ148
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT02268526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02268526.